ADiTx Inc (ADTX)

[Edward]

Aditxt is advancing its negotiations and due diligence under an exclusive LOI to reach a definitive agreement to acquire a biopharmaceutical company that is commercializing a COVID-19 antiviral oral therapy by September 30, 2021.


Could this be the takeover candidate for ADTX------Todos Medical ltd?

Phase 2 Drug Candidate for COVID-19 Todos is developing a more concentrated version of Tollovid for COVID-19 infected patients, using a proprietary blend of botanical extracts with an active chemical ingredient that limits replication of coronaviruses. Todos is currently supporting randomized, placebo-controlled clinical trials managed by JV partner NLC Pharma in Israel. Tollovir is the result of over 15 years of development and an investment of over $18M to date.


https://investor.todosmedical.com/news-events/press-releases/detail/132/todos-medical-receives-trademark-notice-of-allowance-from

Todos Medical Receives Trademark Notice of Allowance from USPTO for Its 3CL Protease Inhibitor Oral Antiviral Drug Candidate Tollovir™